Regend Therapeutics Initiates Phase 1 Clinical Trial of Autologous Cell Therapy REGEND001 for Interstitial Lung Disease
The Emergence of Innovative Lung Regeneration Therapy REGEND001
REGEND001 (Aeriotemcel), developed by Regend Therapeutics, is an autologous cell therapy that utilizes a patient's own bronchial basal stem cells. The therapy involves extracting P63 and KRT5-positive stem cells from the patient's lungs through bronchoscopic brushing, followed by ex vivo expansion and direct injection into damaged lung tissue. This approach aims to fundamentally regenerate the destroyed alveolar structure, unlike existing drugs that only delay disease progression. It is expected to provide a new therapeutic option for patients with interstitial lung disease (ILD), which is characterized by severe lung tissue damage.
KRT5 and P63 Marker-Based Cell Identity and Safety Verification
This Phase 1 clinical trial is in the patient recruitment preparation stage in collaboration with Ruijin Hospital, affiliated with Shanghai Jiao Tong University School of Medicine. Researchers will meticulously verify whether the ex vivo expanded cells maintain the KRT5 and P63 marker expression phenotype essential for lung regeneration. Ensuring the identity of the cells as pure lung progenitor cells and preventing variations during the expansion process is a top priority for the commercialization of stem cell therapies. As this is an early-stage clinical trial, the clinical trial, which will begin in June 2025, will focus on measuring the occurrence of toxicity and immune rejection.
Overcoming the Limitations of Existing Standard Treatments and Market Demand
The current ILD treatment market is dominated by Ofev (Nintedanib) from Boehringer Ingelheim and Esbriet (Pirfenidone) from Roche. However, these antifibrotic drugs only slow down the rate of lung function decline and do not restore already fibrotic tissue, and they have clear limitations such as diarrhea and liver toxicity. In the global idiopathic pulmonary fibrosis (IPF) and ILD market, which is worth approximately $4 billion, there is a high unmet need for innovative next-generation therapies that induce functional recovery. If the Phase 1 clinical trial of REGEND001 is successful, it will open up various possibilities, including combination therapy with existing disease-modifying drugs.
Implications for Global Clinical Expansion and Commercialization
Regend Therapeutics has been continuously exploring the early safety and potential for improvement in carbon monoxide uptake capacity (DLCO) of REGEND001 in various lung diseases, including IPF and chronic obstructive pulmonary disease (COPD). Due to the use of autologous cells, the risk of immune rejection is lower compared to allogeneic cell therapies, which can increase the likelihood of clinical success in the commercial development process. If the Phase 1 ILD clinical trial (NCT06998706) demonstrates the validity of the autologous stem cell transplantation platform, it will be a positive signal for technology transfer and licensing deals in the field of regenerative medicine.
The interstitial lung disease (ILD) treatment market is currently dominated by disease-modifying drugs such as Ofev from Boehringer Ingelheim and Esbriet from Roche; however, the market is expected to grow to approximately $8 billion by 2030, and there is a lack of fundamental lung tissue regeneration therapies. Regend Therapeutics' autologous bronchial basal stem cell transplantation technology, REGEND001, addresses the potential for alveolar structure recovery through KRT5 and P63 marker verification, aiming to overcome the limitations of existing treatment paradigms. The ongoing Phase 1 clinical trial (NCT06998706) has short-term goals focused on demonstrating the biocompatibility of the cell autologous expansion and transplantation platform, with safety and tolerability as key evaluation indicators. In the medium to long term, if Phase 2 clinical trials are initiated and improvements in respiratory function (DLCO, FVC) are confirmed, a reassessment of the high-value biomarker technology and platform value of autologous stem cell therapies may occur in the lung disease regenerative medicine market, which is currently dominated by proprietary standard treatments.
Source: ClinicalTrials.gov (api_ct)